BioSpace News Archive

Pharnext SA announces that the Company has entered into a fixed-rate loan agreement with Global Tech Opportunities 13, a member of the Alpha Blue Ocean group, for a total amount of up to €12 million with an annual interest rate of 9.5%.

Atom Bioscience announced it will update its clinical development of ABP-671, the company’s new oral drug for chronic gout, during a presentation at the BIO International Convention on June 13 – 16, 2022, at the San Diego Convention Center, San Diego, CA.

LumiraDx Limited announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete.

Diopsys, Inc., a leader in modern visual electrophysiology medical devices announced its move to expanded headquarters in Cedar Knolls, New Jersey.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced positive top-line results from MediciNova’s Phase 2 clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome.

CerTest Biotec and BD, a leading global medical technology company, announced a collaboration to develop a molecular diagnostic test for the Monkeypox virus.

KalVista Pharmaceuticals, Inc. presented data for its oral Factor XIIa and plasma kallikrein inhibitor programs at the KININ2022 conference in Annecy, France.

Immunocore Holdings plc announces that the United Kingdom’s Medicines and Healthcare products Regulatory Agency, the Therapeutic Goods Administration in Australia and Health Canada have granted marketing authorization for KIMMTRAK® for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

PathMaker Neurosystems Inc., a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, was selected as a recipient of a START award from MassVentures, which funds deep tech startups based in Massachusetts as they advance technology developed under NIH SBIR/STTR funding.

Immunovant, Inc. announced that it has achieved alignment with the United States Food and Drug Administration Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 clinical trials to evaluate batoclimab in TED.